Anupa Ashar, MD
Internal Medicine · Chandler, AZNPI 1235170093
Payments from drug & device makers
Across 63 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$289
- Abbott$183
- Lilly USA, LLC$135
- AstraZeneca$107
- AbbVie$77
- Astellas Pharma US Inc$60
- plus $440 from 17 others
What the payments were for
- Food & beverage$1,291100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $289 |
| Abbott | 9 | $183 |
| Lilly USA, LLC | 7 | $135 |
| AstraZeneca | 7 | $107 |
| AbbVie | 4 | $77 |
| Astellas Pharma US Inc | 3 | $60 |
| Exact Sciences | 3 | $56 |
| Novartis | 3 | $54 |
| Lucid Diagnostics Inc. | 1 | $47 |
| GSK | 2 | $33 |
| Boston Scientific | 1 | $32 |
| Nevro Corp. | 1 | $23 |
| Renalytix AI, Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Topcon Healthcare Solutions, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Bardy Diagnostics, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Pfizer | 1 | $15 |
How this compares
$1,291 in reported general payments places this provider in the 75th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 60 | $81,760 |
| OzempicSemaglutide | 30 | $74,134 |
| EliquisApixaban | 29 | $29,252 |
| TrulicityDulaglutide | 17 | $23,198 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $21,382 |
| FarxigaDapagliflozin Propanediol | 12 | $19,117 |
| MyrbetriqMirabegron | 13 | $12,472 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,580 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $3,447 |
| Levothyroxine Sodium | 325 | $3,314 |
| Atorvastatin Calcium | 293 | $2,611 |
| Rosuvastatin Calcium | 120 | $2,232 |
| Gabapentin | 99 | $1,896 |
| Losartan Potassium | 164 | $1,867 |
| Omeprazole | 85 | $1,741 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $19 | $81,76060 claims |
| Novo NordiskOzempic | $289 | $74,13430 claims |
| PfizerEliquis | $15 | $29,25229 claims |
| Lilly USA, LLCTrulicity | $135 | $23,19817 claims |
| AstraZenecaFarxiga | $107 | $19,11712 claims |
| Astellas Pharma US IncMyrbetriq | $60 | $12,47213 claims |
| GSKBreo Ellipta | $33 | $6,58016 claims |
| AbbVieSynthroid | $77 | $85520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Chandler
- Janelle WeyerChandler$5.5M
- Randall SeveranceChandler$3.1M
- Punal PatelChandler$604K
- Yessica SachdevaMesa$13.7M
- Louise TaberPhoenix$8.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
- Justin MoserScottsdale$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.